Mylan Settles With Genentech Over Patents for Breast Cancer Drug
Pharmaceutical company Mylan said Monday it has settled with Genentech Inc. and F. Hoffmann-La Roche over patents for Herceptin, its brand name for trastuzumab, a treatment for certain HER2-positive breast cancers. The settlement provides Mylan with global licenses for its trastuzumab product.
from Biotech News
0 Comments